Engraftment of freshly thawed and ex vivo–expanded umbilical cord blood CD34+ cells in nonobese diabetic-severe combined immunodeficiency recipients
| Cell dose × 103 . | Day 0 engraftment . | Day 7 engraftment* . | Day 14 engraftment* . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N† . | Mean‡ . | Range‡ . | N† . | Mean‡ . | Range‡ . | N† . | Mean‡ . | Range‡ . | |
| 20-25 | 6/9 | 1.7 | 0-6 | 7/9 | 4.1 | 0-21 | 4/8 | 2.4 | 0-9 |
| 26-50 | 13/15 | 4.7 | 0-16 | 10/12 | 3.8 | 0-15 | 11/15 | 4.7 | 0-21 |
| 51-75 | 11/16 | 7.4 | 0-21 | 10/15 | 2.7 | 0-24 | 9/9 | 14.7 | 1-57 |
| 76-100 | 9/11 | 9.5 | 0-26 | 9/14 | 7.3 | 0-26 | 5/6 | 8.4 | 0-42 |
| 101-150 | 4/4 | 12.5 | 7-17 | 5/5 | 6 | 2-10 | 5/5 | 7.2 | 1-19 |
| Cell dose × 103 . | Day 0 engraftment . | Day 7 engraftment* . | Day 14 engraftment* . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N† . | Mean‡ . | Range‡ . | N† . | Mean‡ . | Range‡ . | N† . | Mean‡ . | Range‡ . | |
| 20-25 | 6/9 | 1.7 | 0-6 | 7/9 | 4.1 | 0-21 | 4/8 | 2.4 | 0-9 |
| 26-50 | 13/15 | 4.7 | 0-16 | 10/12 | 3.8 | 0-15 | 11/15 | 4.7 | 0-21 |
| 51-75 | 11/16 | 7.4 | 0-21 | 10/15 | 2.7 | 0-24 | 9/9 | 14.7 | 1-57 |
| 76-100 | 9/11 | 9.5 | 0-26 | 9/14 | 7.3 | 0-26 | 5/6 | 8.4 | 0-42 |
| 101-150 | 4/4 | 12.5 | 7-17 | 5/5 | 6 | 2-10 | 5/5 | 7.2 | 1-19 |
Sublethally irradiated nonobese diabetic-severe combined immunodeficiency (NOD-SCID) mice were transplanted with increasing doses of fresh or ex vivo–cultured umbilical cord blood (UCB) CD34+ cells from multiple donors. After 6 weeks, marrow was obtained and the frequency of human CD45+ cells determined by flow cytometry. Results are pooled from 4 independent experiments. At the lower cell doses, 2 to 4 mice were examined per experiment per point.
Cells were expanded for 7 or 14 days in AFT024-noncontact culture supplemented with fetal-liver-tyrosine-kinase-ligand (FL), stem cell factor (SCF), and interleukin 7 (IL-7).
Number of animals engrafted/number of animals that were transplanted.
Percent human CD45+ cells in mouse marrow.